← State exam

72. Tumours of the liver, gallbladder and bile ducts

High yield

Benign liver lesions, metastases, hepatocellular carcinoma, gallbladder cancer and cholangiocarcinoma: diagnosis, staging and resection.

Exam Prep · State examSurgery · HPBSurgery · Surgical oncologySurgical Anatomy · Hepatobiliary

1. Definition

  • Benign liver tumours → haemangioma, focal nodular hyperplasia (FNH), hepatocellular adenoma, simple cysts, biliary cystadenoma
  • Malignant liver tumours:
    • Secondary (metastases) → most common malignant liver tumour (colorectal, neuroendocrine, breast, lung, stomach, pancreas)
    • Primary → hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, fibrolamellar HCC, hepatoblastoma (children), angiosarcoma
  • Gallbladder carcinoma → adenocarcinoma of the gallbladder
  • Cholangiocarcinoma → adenocarcinoma of the bile duct epithelium: intrahepatic, perihilar (Klatskin) or distal

2. Epidemiology

  • Metastases → about 20 times more common than primary liver cancer in the West; 50% of colorectal cancer patients develop liver metastases
  • Haemangioma → most common benign liver tumour (up to 5–20% at autopsy); women
  • FNH → second most common; young women
  • Adenoma → rare; women on the oral contraceptive pill, anabolic steroids, glycogen storage disease, obesity
  • HCC → 6th most common cancer, 3rd cause of cancer death worldwide; Asia and Africa (hepatitis B); men 3 : 1; 80–90% in cirrhosis
  • Gallbladder cancer → most common biliary cancer; women 2–3 : 1; over 65; Chile, India (north), Japan, Eastern Europe
  • Cholangiocarcinoma → rare in the West (1–2 per 100,000); perihilar 50–60%, distal 20–30%, intrahepatic 10–20%; common in Thailand (liver flukes)

3. Aetiology and risk factors

Benign

  • Haemangioma → congenital vascular malformation; may grow in pregnancy
  • FNH → hyperplastic response to an abnormal artery; not hormone-driven
  • Adenoma → oestrogens, androgens, glycogen storage disease, metabolic syndrome; subtypes (HNF1A, inflammatory, beta-catenin mutated → highest cancer risk, sonic hedgehog → bleeding)

HCC

  • Cirrhosis from any cause
  • Hepatitis B (can cause HCC without cirrhosis) and hepatitis C
  • Alcohol
  • Metabolic dysfunction-associated steatotic liver disease (MASLD), diabetes, obesity (rising)
  • Aflatoxin (Aspergillus on stored grain), haemochromatosis, alpha-1 antitrypsin deficiency, Wilson's disease, tyrosinaemia

Gallbladder cancer

  • Gallstones (in 70–90%); large stones (over 3 cm)
  • Porcelain gallbladder (selective mucosal calcification carries more risk)
  • Gallbladder polyps over 1 cm
  • Anomalous pancreaticobiliary duct junction, choledochal cyst
  • Chronic typhoid carriage (Salmonella), obesity, female sex

Cholangiocarcinoma

  • Primary sclerosing cholangitis (lifetime risk 10–20%; often with ulcerative colitis)
  • Choledochal cysts, Caroli's disease
  • Liver flukes → Opisthorchis viverrini, Clonorchis sinensis
  • Hepatolithiasis, recurrent pyogenic cholangitis
  • Hepatitis B and C, cirrhosis, alcohol, MASLD (intrahepatic)
  • Thorotrast (historical), biliary-enteric anastomosis

4. Pathogenesis

  • HCC → chronic injury, regeneration and fibrosis → dysplastic nodules → HCC; arterial blood supply (portal supply lost) → arterial enhancement with washout on imaging; invades the portal vein (tumour thrombus); spreads to lung, bone, adrenal
  • Liver metastases → arrive by the portal vein (gut) or hepatic artery (other sites); mostly supplied by the hepatic artery
  • Gallbladder cancer → dysplasia-carcinoma sequence in chronic inflammation; spreads early:
    • Direct into liver segments IVb and V, duodenum, colon
    • Lymph nodes (cystic, pericholedochal, then coeliac)
    • Peritoneum; port sites after laparoscopic cholecystectomy
  • Cholangiocarcinoma → chronic inflammation and stasis → dysplasia → cancer; grows along and around the ducts (periductal infiltrating), into the portal vein and hepatic artery, along nerves
  • Hilar tumours block both lobes → painless obstructive jaundice

5. Classification

HCC staging: Barcelona Clinic Liver Cancer (BCLC, 2022)

  • 0 (very early) → single tumour < 2 cm, Child-Pugh A, performance status 0 → ablation or resection
  • A (early) → single tumour, or up to 3 nodules all ≤ 3 cm, liver function preserved → resection, transplantation or ablation
  • B (intermediate) → multinodular, preserved liver function, PS 0 → TACE (transplantation if within extended criteria)
  • C (advanced) → portal vein invasion or spread outside the liver, PS 1–2 → systemic therapy (atezolizumab-bevacizumab, durvalumab-tremelimumab; sorafenib, lenvatinib)
  • D (terminal) → end-stage liver function or PS > 2 → best supportive care

Transplantation criteria

  • Milan criteria → one tumour ≤ 5 cm, or 2–3 tumours each ≤ 3 cm; no vascular invasion or spread → 5-year survival over 70%

Cholangiocarcinoma

  • By site → intrahepatic, perihilar (Klatskin), distal
  • Bismuth-Corlette (perihilar):
    • I → below the confluence
    • II → at the confluence
    • IIIa → into the right hepatic duct; IIIb → into the left
    • IV → both secondary ducts, or multifocal

Gallbladder cancer (TNM 8th)

  • T1a lamina propria; T1b muscle; T2 perimuscular tissue (T2a peritoneal side, T2b liver side); T3 serosa or liver invasion; T4 main portal vein, hepatic artery or two or more organs
Table comparing benign liver lesions
Diagram: haemangioma, FNH and adenoma compared

6. Clinical picture

Symptoms

  • Benign lesions → usually none; found by chance ("incidentaloma"); large ones cause RUQ fullness or pain
    • Adenoma → rupture and bleeding (sudden pain, shock), especially in pregnancy
    • Giant haemangioma → rarely Kasabach-Merritt syndrome (platelet consumption)
  • HCC:
    • Often found on surveillance ultrasound in cirrhosis
    • RUQ pain, weight loss, anorexia
    • Decompensation of known cirrhosis → ascites, jaundice, encephalopathy, variceal bleeding
    • Rupture → haemoperitoneum
    • Paraneoplastic → hypoglycaemia, polycythaemia, hypercalcaemia
  • Gallbladder cancer → found in about 1 in 200 cholecystectomy specimens (incidental); otherwise late: RUQ pain, weight loss, jaundice (spread to the hilum), mass
  • Cholangiocarcinoma → painless progressive jaundice, itch, dark urine, pale stools, weight loss; cholangitis after stenting; intrahepatic → pain, mass, no jaundice

Signs

  • Hepatomegaly, hard irregular liver
  • Bruit over the liver (HCC, vascular tumour)
  • Signs of chronic liver disease
  • Jaundice; palpable gallbladder only in distal duct tumours (Courvoisier); in hilar tumours the gallbladder is collapsed
  • Ascites, Virchow's node, Sister Mary Joseph nodule (advanced)

7. Diagnosis

Blood tests

  • LFT, INR, albumin, platelets (liver function and portal hypertension)
  • Alpha-fetoprotein (AFP) → HCC (raised in about 60%); also hepatoblastoma, germ cell tumours
  • CA 19-9 → cholangiocarcinoma, gallbladder cancer (also high in cholangitis and jaundice); CEA
  • Hepatitis B and C serology
  • Child-Pugh and MELD scores

Imaging

  • Ultrasound → first test; 6-monthly surveillance ± AFP in cirrhosis and high-risk hepatitis B
  • Multiphase contrast CT or MRI:
    • HCC → arterial hyperenhancement with portal venous or delayed washout and a capsule (LI-RADS 5) → diagnosis without biopsy in cirrhosis
    • Haemangioma → peripheral nodular enhancement filling in centripetally
    • FNH → arterial enhancement with a central scar; retains hepatobiliary (gadoxetate) contrast
    • Adenoma → arterial enhancement; fat or bleeding; no gadoxetate uptake (most)
  • MRCP → level and extent of biliary tumours (Bismuth type)
  • CT chest, abdomen and pelvis → staging; PET-CT in selected
  • Liver volumetry → future liver remnant before major hepatectomy

Tissue

  • Biopsy → when imaging is not typical; metastases of unknown primary; before systemic therapy; not needed for resectable typical HCC
  • ERCP with brushings or cholangioscopy biopsy → biliary strictures (low sensitivity); EUS-FNA for distal tumours
  • Staging laparoscopy → gallbladder cancer, perihilar cholangiocarcinoma (peritoneal spread)

Liver function before surgery

  • Child-Pugh class, MELD, hepatic venous pressure gradient (≥ 10 mmHg → high risk), indocyanine green clearance

8. Differential diagnosis

  • Liver lesions → abscess, hydatid cyst, simple cyst, regenerative nodules in cirrhosis, focal fat, metastases
  • Biliary stricture → benign (PSC, IgG4 cholangiopathy, after surgery, Mirizzi), pancreatic cancer, gallbladder cancer at the hilum
  • Gallbladder → xanthogranulomatous cholecystitis, adenomyomatosis, cholesterol polyps

9. Treatment

Conservative

  • Haemangioma and FNH → no treatment, no follow-up when the diagnosis is certain; FNH → may continue the oral contraceptive pill
  • Adenoma:
    • Stop the oral contraceptive pill, lose weight; repeat MRI in 6–12 months
    • Under 5 cm in women → observe
  • Gallbladder polyps → ultrasound follow-up if 6–9 mm (more often with risk factors)
  • HCC non-surgical:
    • Ablation (radiofrequency or microwave) → tumours ≤ 3 cm; as good as resection for small tumours
    • TACE (transarterial chemoembolisation) → intermediate stage; bridge to transplant
    • TARE / SIRT (yttrium-90 radioembolisation), stereotactic radiotherapy
    • Systemic → atezolizumab with bevacizumab or durvalumab with tremelimumab first-line; lenvatinib or sorafenib
    • Treat the liver disease → antivirals for hepatitis B and C, stop alcohol
  • Cholangiocarcinoma and gallbladder cancer:
    • Adjuvant capecitabine for 6 months after resection (BILCAP)
    • Advanced → gemcitabine, cisplatin and durvalumab (TOPAZ-1) or pembrolizumab
    • Targeted therapy for FGFR2 fusions (pemigatinib) and IDH1 mutations (ivosidenib) in intrahepatic tumours
    • Biliary drainage for jaundice and cholangitis → metal stent (ERCP or PTBD); photodynamic therapy or radiofrequency ablation of the stent

Surgical

  • Adenoma → resect if over 5 cm, in men (any size), beta-catenin mutated, growing, or bleeding (embolise first if ruptured)
  • Liver metastases (colorectal):
    • Resect if all disease can be removed with clear margins and an adequate future liver remnant (over 20–25% in a normal liver, 30% after chemotherapy, 40% in cirrhosis)
    • Perioperative chemotherapy (FOLFOX); 5-year survival after resection about 40–50%
    • Small liver remnant → portal vein embolisation, two-stage hepatectomy, ALPPS
    • Ablation for small deep lesions
    • Neuroendocrine metastases → resection or debulking
  • HCC:
    • Resection → single tumour, Child-Pugh A, no clinically significant portal hypertension, normal bilirubin; anatomical resection preferred
    • Liver transplantation → within Milan criteria with cirrhosis; treats the tumour and the cirrhosis; 5-year survival over 70%
  • Gallbladder cancer:
    • T1a found after cholecystectomy → cholecystectomy is enough (if margins and cystic duct are clear)
    • T1b or more → re-resection: segment IVb and V resection (or wedge of 2 cm of liver bed) with regional lymphadenectomy (hepatoduodenal ligament), ± bile duct resection if the cystic duct margin is positive
    • Suspected cancer before surgery → no laparoscopic cholecystectomy; open radical cholecystectomy
    • Port-site excision → no longer routine
  • Cholangiocarcinoma:
    • Perihilar → hepatectomy (extended right or left) with caudate lobe and bile duct resection, lymphadenectomy and Roux-en-Y hepaticojejunostomy; preoperative drainage of the future liver remnant and portal vein embolisation
    • Liver transplantation for selected unresectable perihilar tumours (Mayo protocol: chemoradiotherapy then transplant)
    • Distal → pancreaticoduodenectomy (Whipple)
    • Intrahepatic → hepatectomy with lymphadenectomy
  • Unresectable → biliary bypass rarely (when found at laparotomy)
Flowchart of the management of hepatocellular carcinoma by BCLC stage
Diagram: hepatocellular carcinoma, by BCLC stage

10. Complications

  • Disease → rupture and bleeding (adenoma, HCC), obstructive jaundice, cholangitis, liver failure, portal vein thrombosis, cachexia
  • Liver resection:
    • Post-hepatectomy liver failure (small remnant, cirrhosis) → main cause of death
    • Bile leak, biloma
    • Bleeding, subphrenic abscess, pleural effusion
  • Transplantation → rejection, infection from immunosuppression, recurrence of HCC (about 10–15%)
  • TACE → post-embolisation syndrome (fever, pain, nausea), liver failure

Prognosis

  • HCC → 5-year survival under 20% in all patients; 60–80% after resection or transplant for early disease
  • Gallbladder cancer → 5-year survival under 10–20% in all; good for T1 tumours
  • Cholangiocarcinoma → 5-year survival 20–40% after R0 resection; median survival under 1 year if unresectable

Mind map Pinch or scroll to zoom · drag to move

Show as a list

Liver and biliary tumours

  • Benign
    • Haemangioma: leave
    • FNH: central scar, leave
    • Adenoma: pill, resect > 5 cm
  • Metastases
    • Commonest malignancy
    • Colorectal: resect
    • Future liver remnant
    • PVE, ALPPS
  • HCC
    • Cirrhosis, hepatitis B, C
    • AFP
    • Arterial washout
    • BCLC staging
    • Resect, ablate, transplant
    • TACE
    • Atezolizumab + bevacizumab
  • Gallbladder cancer
    • Gallstones, porcelain
    • T1b+: re-resection IVb, V
  • Cholangiocarcinoma
    • PSC, flukes, cysts
    • Klatskin: Bismuth I-IV
    • Hepatectomy + caudate
    • Distal: Whipple
    • Gem-cis + durvalumab

More in State exam